Showing 3801-3810 of 5621 results for "".
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of
- MSU Researchers Discover Link Between Cholesterol and Diabetic Retinopathyhttps://modernod.com/news/msu-researchers-discover-link-between-cholesterol-and-diabetic-retinopathy/2481822/Research led by Michigan State and other universities found that diabetes, age-related health conditions, and other metabolic disorders can lead to a buildup of cholesterol in the retina. This tends to crystalize and contribute to the development of diabetic retinopathy. Cryst
- Alcon to Showcase New Data and Innovation to Support Ophthalmic Surgical Teams at ESCRShttps://modernod.com/news/alcon-to-showcase-new-data-and-innovation-to-support-ophthalmic-surgical-teams-at-escrs/2481815/Alcon will present a lineup of scientific data at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) Sept. 8-12 in Vienna, Austria. Alcon will showcase product updates designed to deliver patient outcomes and operational efficiencies for ophthalmologists an
- BVI Expands its Presence in Spain and Portugal Acquiring Medical Mixhttps://modernod.com/news/bvi-expands-its-presence-in-spain-and-portugal-acquiring-medical-mix/2481813/BVI announced it has acquired Medical Mix, an ophthalmic medical device supplier in Spain and Portugal. Financial terms of the deal were not disclosed. BVI said its European footprint with direct sales representatives and infrastructure now spans all major western Eu
- Rayner Unveils Enhancements to Digital Platforms at ESCRS 2023https://modernod.com/news/rayner-unveils-enhancements-to-digital-platforms-at-escrs-2023/2481808/Rayner has announced a series of updates to its digital platforms, RayPRO and Peer2Peer, designed to redefine patient-reported outcome measures (PROMs) and elevate clinical ophthalmic education. Attendees of the ESCRS 2023 congress are invited to explore these advancements at Booth B303
- EyeSouth Partners Affiliates with Retina and Vitreous of Texashttps://modernod.com/news/eyesouth-partners-affiliates-with-retina-and-vitreous-of-texas/2481807/EyeSouth Partners has announced that it has partnered with Retina and Vitreous of Texas (RVT), in Houston. The affiliation represents EyeSouth’s 38th overall and the network’s first retina-only affiliation in the state of Texas. Financial terms of the deal were not disclosed
- OcuCell Secures Funding from The Eye-Bank for Sight Restorationhttps://modernod.com/news/ocucell-secures-funding-from-the-eye-bank-for-sight-restoration/2481804/Ocular cell therapy company OcuCell announced it has received seed funding from The Eye-Bank for Sight Restoration (EBSR). The funding will enable OcuCell to accelerate its mission of transforming the corneal cell therapy landscape through the development of cell therapy solut
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- ScienceBased Health Welcomes New Members to Its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-welcomes-new-members-to-its-optometry-clinical-advisory-panel/2481787/ScienceBased Health (SBH) announced the addition of Jaclyn Garlich, OD, FAAO; Jacob Lang, OD, FAAO, Dipl ABO; and Mark Schaeffer, OD to its Optometry Clinical Advisory Panel. ScienceBased Health develops and markets e